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Background: Limited controlled data exist to guide treatment choices for clinicians caring for patients with major
depressive disorder (MDD). Although many putative predictors of treatment response have been reported, most
were identified through retrospective analyses of existing datasets and very few have been replicated in a manner
that can impact clinical practice. One major confound in previous studies examining predictors of treatment
response is the patient’s treatment history, which may affect both the predictor of interest and treatment
outcomes. Moreover, prior treatment history provides an important source of selection bias, thereby limiting
generalizability. Consequently, we initiated a randomized clinical trial designed to identify factors that moderate
response to three treatments for MDD among patients never treated previously for the condition.
Methods/design: Treatment-naïve adults aged 18 to 65 years with moderate-to-severe, non-psychotic MDD are
randomized equally to one of three 12-week treatment arms: (1) cognitive behavior therapy (CBT, 16 sessions);
(2) duloxetine (30–60 mg/d); or (3) escitalopram (10–20 mg/d). Prior to randomization, patients undergo multiple
assessments, including resting state functional magnetic resonance imaging (fMRI), immune markers, DNA and
gene expression products, and dexamethasone-corticotropin-releasing hormone (Dex/CRH) testing. Prior to or
shortly after randomization, patients also complete a comprehensive personality assessment. Repeat assessment of
the biological measures (fMRI, immune markers, and gene expression products) occurs at an early time-point in
treatment, and upon completion of 12-week treatment, when a second Dex/CRH test is also conducted. Patients
remitting by the end of this acute treatment phase are then eligible to enter a 21-month follow-up phase, with
quarterly visits to monitor for recurrence. Non-remitters are offered augmentation treatment for a second 12-week
course of treatment, during which they receive a combination of CBT and antidepressant medication. Predictors of
the primary outcome, remission, will be identified for overall and treatment-specific effects, and a statistical model
incorporating multiple predictors will be developed to predict outcomes.
Discussion: The PReDICT study’s evaluation of biological, psychological, and clinical factors that may differentially
impact treatment outcomes represents a sizeable step toward developing personalized treatments for MDD.
Identified predictors should help guide the selection of initial treatments, and identify those patients most
vulnerable to recurrence, who thus warrant maintenance or combination treatments to achieve and maintain
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Major depressive disorder (MDD) is a common, frequently
chronic, disabling, and debilitating psychiatric disorder.
Approximately 17% of US citizens will at some point in
their lives experience MDD with roughly twice as many
females as males suffering from the disorder [1]. A widely
cited study, Global Burden of Disease, a collaboration of
the World Bank, the World Health Organization, and the
Harvard School of Public Health, reported that MDD was
the fourth most disabling disorder, and predicted that by
2020 MDD would be the second leading cause of disability
worldwide, trailing only coronary artery disease [2].
Although it is difficult to ascertain the financial burden of
MDD, one well-conducted study in the US found that
among primary care patients, healthcare costs of indivi-
duals suffering from MDD were twice those of individuals
without MDD [3]; these differences resulted largely from
increased healthcare costs associated with depressed
patients’ utilization of medical services at four times the
rate of patients who did not suffer from depression.
The initial onset of MDD occurs most frequently be-
tween the ages of 15 years and 29 years, and recent stud-
ies have found that approximately 50% of teenagers who
are diagnosed with MDD experience a second episode
by the age of 25 years [4,5]. One particularly problematic
aspect of MDD is the increased likelihood for recurrence
following each successive episode [6] with an ultimate
mean of approximately 5 years between episodes [7].
Furthermore, MDD is associated with an increased risk
of medical disorders, including cardiovascular and endo-
crine diseases [8-10]. In sum, MDD frequently begins
during the teenage and early adult years, and it con-
tinues over the life span causing substantial negative so-
cial, economic, and health effects [11]. The past few
decades have witnessed the development and evaluation
of new antidepressant medications and psychotherapies
for MDD [12,13]. Despite these advances, depression
treatment continues to be hampered by two major lim-
itations: an unacceptably low rate of symptomatic remis-
sion, and the virtual absence of any practical predictors
of treatment response, whether partial or complete. Al-
though it is widely considered that current interventions
benefit approximately 60% of MDD patients, only about
30% to 40% of patients show full remission of their
symptoms as defined by the MacArthur criteria (for ex-
ample, a 17-item Hamilton Depression Rating Scale
(HDRS) score <8) [14,15]. Approximately 30% moredemonstrate some response to treatment, indicating they
experience clinically important reductions in their de-
pressive symptom burden, yet also continue to experi-
ence clinically important residual symptoms. Patients
who experience a response short of remission are more
vulnerable to relapses and recurrences of the disorder
[16] and experience greater functional disability [17].
Current treatment for MDD involves a trial-and-error
approach because there are no consistently identified
predictors of differential response across treatment mo-
dalities. Primary first-line treatments consist of either an
evidence-based form of psychotherapy or antidepressant
medication. In patients treated pharmacologically, sev-
eral treatment options are available, but there are very
few clinical trial data to guide clinicians as to which first
step enhances the odds of remission for an individual
patient [18]. Illustrating the importance of such trials,
one retrospective study found a differential advantage
for psychotherapy over medication (nefazodone) in
chronically depressed patients with early life trauma
[19]. A treatment regimen that ultimately proves to be
ineffective results in continuing patient distress and role
dysfunction, discouragement regarding possible relief
from MDD, exposure to potential side effects, and un-
necessary medical costs. Among the roughly 70% of
depressed patients who do not remit with their first
treatment, many do not return to explore other treat-
ment options that might have proven effective [20].
Previous efforts attempting to identify predictors of
treatment response have typically been post-hoc analyses
of datasets designed to test other hypotheses [18]. Numer-
ous predictors have been identified by this approach, but
they lack consistent prospective validation, and such pre-
dictive studies generally examine a single treatment.
Examples of potential demographic predictors of treat-
ment response have included age, gender, marital status,
family history of treatment response, and socioeconomic
factors [15]. Clinical predictors have included diagnostic
subtype [21,22], severity of depression [23], chronicity
[15], symptom profiles [24], patient treatment preference
[25], early life stress [19], personality profiles [26], previ-
ous treatment [27], psychomotor speed [28], and co-
morbid diagnoses [29]. Physiologic predictors have
included auditory evoked potentials [30], event-related
potentials [31], and quantitative electroencephalograms
[32]. Biochemical and endocrinology predictors include
hypothalamic-pituitary-adrenal (HPA) axis measures [33],
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and serotonergic measures in serum/platelets [35]. Im-
aging predictors have included pre-treatment patterns of
regional glucose metabolism and blood flow measured
with positron emission tomography (PET) [36], as well as
structural and functional magnetic resonance imaging
(fMRI) studies [37].
With rare exception, the previously noted studies have
retrospectively examined patterns correlated to out-
comes for a specific treatment. A few have tracked dif-
ferences between responders and non-responders to two
different treatments, for example drug vs. psychotherapy
or drug vs. drug [38]. Numerous attempts at identifying
genetic polymorphisms as predictors of treatment for
MDD have been made [39]. So far, except for some poly-
morphisms directly influencing the pharmacokinetics of
antidepressant drugs [40], no consistently replicated
(and thus clinically relevant) candidates have emerged
from candidate gene or genome-wide association studies
[41]. This suggests that genetic information may need to
be combined with other biomarkers and clinical vari-
ables for a more reliable prediction of response [42]. In
addition, few previous studies have investigated genetic
polymorphisms as differential predictors for different
types of antidepressant treatments [43].
One of the strategic objectives of the National Institute
of Mental Health (NIMH) is to develop better, more spe-
cific interventions for patients with mental illnesses; this
approach is broadly known as ‘personalized medicine’. In
the field of mental health, personalized medicine has come
to encompass the moderators and mediators of treatment
response, including biological, genetic, behavioral, experi-
ential, clinical, and environmental factors [44]. Personalized
medicine may gain additional importance with the
increases in racial and ethnic diversity predicted by the US
Census Bureau [45]. Before these NIMH goals and objec-
tives were fully articulated, we developed the Emory
Predictors of Response in Depression to Individual and
Combined Treatments (PReDICT) study that commenced
recruitment in January 2007.
Aims
The primary aim of PReDICT is to identify predictors of
remission with acute treatment for MDD; predictors
comprise genetic, endocrine, immune, and personality
measures, as well as baseline and early-treatment fMRI
of the central nervous system. Predictors will be identi-
fied by utilizing sophisticated multivariate procedures to
determine which variables have clinically important and
statistically significant effects for the prediction of remis-
sion and response.
A secondary aim of the project is to identify predictors
of recurrence of major depression during a 21-month




Four hundreda treatment-naïve patients with a primary
diagnosis of MDD and HDRS-17 scores ≥18 at screening
and ≥15 at the baseline visit are to be randomly assigned
equally to one of three possible treatments: (1) a select-
ive serotonin reuptake inhibitor (SSRI, escitalopram); (2)
a serotonin norepinephrine reuptake inhibitor (SNRI,
duloxetine); or (3) individual cognitive behavior therapy
(CBT). Initial treatment consists of a 12-week course
with one of these monotherapies. Patients who meet cri-
teria for full remission of their MDD are followed for a
21-month follow-up phase to monitor for depression re-
currence. Patients who do not remit after the 12-week
monotherapy acute treatment phase are offered another
12 weeks of acute treatment, during which they receive
combination therapy with study medication plus CBT.
The overall study design is presented in Figure 1.
The study was designed and is being conducted in ac-
cord with the latest version of the Declaration of Helsinki
[46]. The Emory Institutional Review Board and the Grady
Hospital Research Oversight Committee gave ethical ap-
proval for the study design, procedures, and recruitment
strategies (Emory IRB numbers 00024975 and 00004719).
Study participants
The study’s total targeted enrollment is 400 18-65-year
-old men and women who meet DSM-IV defined criteria
for current major depressive disorder (MDD) and who
have never previously received treatment for a mood
disorder. Patients with acute, recurrent, or chronic
MDD are included. The study excludes psychotic sub-
type of MDD, seasonal affective disorder, and pregnant
or breast-feeding women. All interested patients undergo
a telephone screening to assess preliminary eligibility,
and potentially eligible patients are then scheduled for
an in-office screening visit. Patients are not paid for par-
ticipation during the acute phases, but they do receive
the equivalent of approximately $5 per visit to offset
travel-related costs. Patients entering into the follow-up
phase receive $50 per visit to compensate for their time
and inconvenience. The fundamental reason for examin-
ing treatment-naïve patients is to avoid confounding the
biology of the illness with the effects of previous treat-
ment, an effect that might result in persistent biological
changes. Although the strictest definition of treatment-
naïve would be patients who have not received a single
dose of an antidepressant/psychotropic or a single ses-
sion of formal individual psychotherapy, defining treat-
ment naiveté so strictly is unnecessarily restrictive and
reduces the feasibility of recruiting the targeted number of
Figure 1 PReDICT study design.
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treatment (and therefore study ineligibility) as treatment
for MDD, dysthymia, or depressive disorder not otherwise
specified with either: (1) a marketed antidepressant at a
minimum effective dose for 4 or more consecutive weeks;
or (2) four or more sessions of an established structured
psychotherapy for depression, that is CBT, behavior ther-
apy, interpersonal therapy (IPT), or behavioral marital
therapy. Patients who have received supportive therapy or
other forms of therapy are eligible, regardless of the dur-
ation of their previous psychotherapy course.
Study sites
The study is being performed at three Atlanta sites asso-
ciated with the Emory University School of Medicine
Department of Psychiatry and Behavioral Sciences. The
primary site, where all assessments are conducted in
English, is located on the campus of Emory University,
in suburban Atlanta. A second English-speaking satellite
site, located in Stockbridge, GA, was added to the study
in July 2011. This site is open 2 days per week, and oper-
ates with the same personnel and randomization and
blocking schedule as the primary site. The third site is
located in the International Medical Center (IMC) at
Grady Memorial Hospital in downtown Atlanta. This
site is staffed entirely by bilingual (English/Spanish) and
bicultural personnel, who also participate in the study at
the primary site. All assessments at the IMC site are
conducted in Spanish, employing validated translations
of the rating scales and self-reports. Instruments without
a previously validated translation and CBT materials
were translated and evaluated by an expert panel. A
Spanish-language site was established to assure a more
diverse and representative study population, recognizing
that Hispanics are the largest and fastest growing minor-
ity group in the US [45]; this site employs a separate
randomization and blocking schedule from the primary
Emory site. The Dexamethasone-Corticotropin Releasing
Hormone tests (Dex/CRH) (see below) are conducted in
the Clinical Interaction Network (CIN) of the Atlanta
Clinical and Translational Science Institute at both
Emory and Grady Hospitals. Study fMRIs for patients
treated through both sites are conducted at the Emory
University Biomedical Imaging Technology Center.
Screening and treatment assessments
The schedule of assessments is presented in Figure 2. After
signing the informed consent form, study participants meet
with a staff member for an initial psychiatric interview. The
results of this initial interview are then presented to a study
psychiatrist, who subsequently conducts a 30 to 60-min
diagnostic evaluation, including medical history and previ-
ous treatment history. Patients who remain eligible then
complete the Structured Clinical Interview for DSM-IV(SCID) [47,48] administered by a trained clinical inter-
viewer. Symptom severity is assessed by the SCID inter-
viewer who also administers the HDRS-24 plus atypical
items [49,50] using a structured interview guide [51],
Montgomery-Asberg Depression Rating Scale (MADRS)
[52,53], Hamilton Anxiety Rating Scale (HARS) [54], and
Clinical Global Impression scale for Severity (CGI-S) [55].
Patients are then evaluated to ensure adequate physical
health and to identify potential medical causes for a major
depressive episode. This evaluation includes: a medical re-
view of systems, physical exam, electrocardiogram and la-
boratory assessments (comprehensive metabolic panel,
complete blood count, thyroid-stimulating hormone level,
pregnancy test, and urinalysis and urine drug screen).
Demographic variables and family history of psychiatric ill-
ness are collected via self-report. Childhood trauma history
is assessed via the Childhood Trauma Questionnaire
(CTQ) [56] and the Early Home Environment Interview
(EHEI) [57]. Inclusion and exclusion criteria are listed
below. Patients who meet all eligibility criteria undergo
phlebotomy for measurement of inflammatory markers and
extraction of mRNA and DNA. Subsequently, patients
complete the fMRI and a half-day CIN outpatient hospital
stay during which the Dex/CRH test is performed. The tar-
geted time to complete all pre-treatment assessments from
screening to randomization is 10 days.
Inclusion criteria
1. Male or female outpatients aged between 18 and
65 years old
2. Primary psychiatric diagnosis of DSM-IV-defined
major depressive disorder
3. Total HDRS-17 score ≥18 at screening visit, AND
≥15 at randomization visit
4. Never previously treated for MDD or dysthymia,
defined as:a. Four or more consecutive weeks of an
antidepressant at minimally effective dose, OR
b. Four or more sessions of an established
structured psychotherapy for depression, i.e. CBT,
BT, IPT, or behavioral marital therapy
5. Able to independently understand and provide
written informed consent
6. Able to communicate fluently in either English or
Spanish
Exclusion criteria
1. Current DSM-IV defined psychotic disorder, eating
disorder, dissociative disorder, obsessive compulsive
disorder, or dementia
Figure 2 Schedule of events for PReDICT study. NOTE: Remitters to the acute (monotherapy) treatment phase enter into the extension
follow-up phase beginning at week 12. BDI, Beck Depression Inventory; CGI, Clinical Global Impression; CTQ, Childhood Trauma Questionnaire:
Dex/CRH, Dexamethasone Corticotropin Releasing Hormone test; DHUS, Daily Hassles and Uplifts Scale; DNA, Deoxyribonucleic acid; EHEI, Early
Home Environment Interview; HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton Depression Rating Scale; IPDE, International Personality
Disorders Examination; LES, Life Experiences Survey; LIFE, Longitudinal Interview Follow-up Evaluation; MADRS, Montgomery Depression Rating
Scale; MRI, Magnetic resonance imaging; mRNA, Messenger ribonucleic acid; PABS, Patient Attitudes and Beliefs Scale; PE, Physical Exam; QIDS,
Quick Inventory of Depressive Symptoms; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; SCID, Structured Clinical Interview for
DSM-IV; SDS, Sheehan Disability Scale; SWAP, Shedler-Westen Assessment Procedure, 2nd Ed.
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major depressive disorder
3. Lifetime history of DSM-IV defined bipolar disorder
or schizophrenia
4. Current clinically important suicidal ideation
requiring rapid initiation of treatment
5. Meeting DSM-IV criteria for alcohol or drug
dependence within 12 months, or substance abuse
within 3 months of randomization visit (excluding
nicotine and caffeine)
6. Urine drug screen positive for drugs of abuse at
screening visit
7. Any lifetime prior exposure to citalopram,
escitalopram, or duloxetine
8. Any lifetime adequate medication treatment
(≥4 weeks at minimal effective dose) for major
depression or dysthymia
9. Any lifetime prior treatment with four or more
sessions of an established structured psychotherapyfor depression, i.e. CBT, BT, IPT, or behavioral
marital therapy
10.Treatment with any dose (including less than
minimally effective dose) of an antidepressant for any
reason for ≥4 weeks for during the current episode
11.Use of any psychotropic medication (except
hypnotics) within 1 week of the screening visit
12.Any use of fluoxetine within 8 weeks of the
screening visit
13.Need for concurrent neuroleptic or mood stabilizer
therapy
14.Currently pregnant or breast-feeding women
15.Any current acute or chronic medical disorder that
would likely affect or preclude completion of the
study
16.Clinically important neurological, inflammatory,
autoimmune, endocrine, or other medical illness
that could interfere with the conduct of the study or
interfere with interpretation of study results,
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laboratory results
17.Medical contraindications which would preclude
treatment with escitalopram or duloxetine
18.Presence of any factors that would likely prevent the
patient from completing 12 weeks of the study
19.Contraindications for MRI, such as pacemaker,
aneurysm clips, or other implants
20.Unlikely to comply with the study protocol, as
judged by a study psychiatrist
Randomization
Following completion of the predictors assessments,
patients participate in the baseline assessments and
are randomized. Self-report measures of depression
severity at this baseline visit include the Quick Inven-
tory of Depressive Symptoms-Self Report (QIDS-SR)
[58] and the Beck Depression Inventory (BDI) [59,60].
Quality of life is assessed with the Qualitative Life
Enjoyment Satisfaction Questionnaire (Q-LES-Q) [61]
and the Sheehan Disability Scale (SDS) [62,63].
Patients also complete an abbreviated version of the
Patient Attitudes and Beliefs Scale (PABS) [64], to in-
dicate their treatment preference and their beliefs
about the causes of their depression, and the Life
Experiences Survey [65] to assess important personal
events over the previous 12 months. A blinded rater
administers the HDRS-24, HARS, MADRS, CGI-S,
and CGI-Improvement (CGI-I) [55]. To be rando-
mized, patients must score ≥15 on the HDRS-17 total
score at this visit.
A permuted block randomization pattern was gener-
ated prior to opening enrollment for the study. Ran-
domized treatment assignments were individually
printed and placed in sealed opaque envelopes by
Emory employees uninvolved in the study. The
randomization envelopes were stored in the research
offices and opened sequentially at the time of each
patient’s randomization visit. The treatment assign-
ment was generated using randomized permuted
blocks, stratified by site, to ensure equal allocation
across treatment groups within the English- and




A similar proportion of MDD patients respond acutely to
any single class of antidepressant medications [66]. Meta-
analyses using remission as the outcome criterion indi-
cated a potential advantage for medications with dual
effects on serotonin and norepinephrine (primarily venla-
faxine) over SSRIs [67]. However, the number needed to
treat to achieve an additional remission with an SNRI vs.SSRI is high, and of doubtful clinical importance. A
pooled analysis of six phase II/III trials comparing duloxe-
tine to an SSRI (fluoxetine or paroxetine) found no differ-
ence in remission rates between medication classes [68].
Meta-analyses of the efficacy of escitalopram have found it
to be as good or better than SNRI treatment for MDD
[69,70]. However, some patients clearly respond to certain
antidepressants but not others, indicating the need to
identify differential predictors of response for these
treatments.
The patent-holding companies provide the medications
at no cost to the study. Bulk-shipped medication is com-
pounded in the Emory investigational drug service phar-
macy and packaged in purple capsules. Each capsule
contains either escitalopram oxalate (equivalent to 10 mg
of escitalopram free base) or duloxetine HCl (equivalent to
30 mg of duloxetine free base). All patients are started on
one capsule per day, dosed in the morning with food. If
daytime sedation occurs, the psychiatrist may change dos-
ing to bedtime. If the patient does not demonstrate clinic-
ally meaningful improvement by week 4, the dose is raised
to two capsules per day, though the treating psychiatrist,
based on the severity of the patient‘s symptoms, may raise
the dose earlier if deemed necessary. If there is a plateau in
response, or if remission is not achieved by week 6, the
dose is increased to two capsules per day. If adverse events
are sufficiently distressing to the patient, the dose can be
lowered back to one capsule per day. Patients eligible for
the follow-up phase of PReDICT are strongly encouraged
to remain on medication through month 12, at which time
the psychiatrist discusses with the patient the risks and ben-
efits of discontinuing the medication given their respective
number of prior untreated depressive episodes. Regardless
of their decision to continue or discontinue medication at
this stage, patients continue into the second year of follow-
up. The physicians overseeing medication treatment are all
board-certified psychiatrists or fourth-year psychiatry resi-
dents under close supervision of the lead study psychiatrist
(BWD).
We will measure concentrations of escitalopram and
duloxetine primarily to evaluate adherence but also to
monitor individual subjects’ metabolism and clearance of
the medications. The assay utilizes a validated liquid chro-
matography tandem mass spectroscopic method to assess
concentrations of all commonly used antidepressants and
has a limit of detection of 0.2 ng/mL [71]. Absolute recov-
eries vary from 88.9% to 119.6% and inter-assay imprecision
varies from 3% to 13% at levels of 75 and 300 ng/mL, for
all compounds. The method compares favorably with the
HPLC-UV methods used previously in our laboratory [72].
Serum is collected at baseline, week 2 and week 12 (and
week 14 and 24 if in combination treatment) to assess
medication adherence. These samples will be batch pro-
cessed after study completion; consequently, they will not
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patients during their study treatment.
Cognitive behavior therapy (CBT)
CBT was selected as the non-pharmacological treatment
for this study because of its well-documented clinical effi-
cacy in depressed patients at all levels of depression sever-
ity and chronicity [12]. It offers specific advantages over
other psychotherapies for a study of this type. Specifically,
the therapeutic process has been validated and the general
goals and procedures for each session are standardized
with available published training manuals [73]. Training
and competence measures can be evaluated to insure a
consistent standard of care for all patients.
The CBT package employed in the PReDICT study uti-
lizes a standardized treatment protocol [73]. CBT pursues
symptomatic relief from depression through a systematic
effort to change depressed patients’ automatic and mal-
adaptive ways of thinking. At the heart of this approach is
the assumption that distorted views about the self, the
world, and the future maintain depressive affect. Patients
first work at becoming aware of these thinking styles, and
then learn ways of thinking differently so that their cogni-
tive processes become more adaptive. These skills, when
accompanied by affective arousal and practiced in the con-
text of extra homework assignments, are an important en-
gine of symptom resolution [74]. Patients are first asked to
record or keep track of their thoughts, especially those
accessed in the midst of problematic emotional situations.
During the course of treatment, the therapist gradually
moves the focus of therapy from these distorted cognitions
about themselves, the world, and the future to identifica-
tion and modification of the underlying depressogenic
maladaptive cognitive processes or errors. Finally, the pa-
tient comes to understand the beliefs underlying the cog-
nitive processes and self-statements, and the therapy
focuses on helping the patient change the underlying erro-
neous beliefs.
The typical course of CBT comprises 12 to 20 1-h ses-
sions; in this study, 16 sessions are provided. The se-
quence of therapy involves three stages. In the early stage
(sessions 1 to 4) the emphasis is on establishing a thera-
peutic relationship with the patient, educating the patient
about the cognitive model and emotional lability, setting
goals, and identifying, eliciting, and evaluating automatic
thoughts. The middle phase (sessions 5 to 12) involves a
gradual shift towards the identification of dysfunctional
beliefs and compensatory strategies the patient may be
employing, helping the patient to: (1) identify dysfunc-
tional cognitive processes (for example, overgeneralization,
mind reading) and core beliefs or schema; and (2) practice
skills at responding to and modifying depressogenic pro-
cesses and schema. Tasks in the late stage of CBT (ses-
sions 13 to 16) revolve around preparing the patient fortermination, predicting high-risk situations relevant to re-
lapse, and consolidation of learning self-therapy tasks. To
complete the 16 visits during the 12 weeks of intervention,
patients randomized to CBT see their therapist twice per
week for the first 4 weeks and then weekly for the
remaining 8 weeks. The number of sessions attended is
tracked for each patient.
Doctoral-level and masters-level providers trained in
the specific CBT protocol for the study will provide the
therapy. Patients who complete at least 12 sessions of
CBT will be considered to have completed the course of
CBT. All CBT-treated patients continuing in the study
after week 12 receive three booster sessions at monthly
intervals over the first 3 months and another three
booster sessions, each separated by at least 1 month,
during the second year of follow-up. There is also one
additional crisis session available to patients during each
year of follow-up. All therapy sessions are videotaped,
and an independent off-site CBT expert at Beck’s
Institute of Cognitive Therapy rates selected sessions of
all therapists’ competence in Beck’s type of CBT [73].
Acute monotherapy phase assessment visits
All patients are seen for symptom severity ratings visits
weekly for the first 6 weeks and bi-weekly for the
remaining 6 weeks of the acute phase. At each visit, the
patient completes the BDI and QIDS, and undergoes as-
sessment with the HDRS, MADRS, and HARS with a
blinded rater. All patients also meet with a study psych-
iatrist for assessment of CGIs, concomitant medications,
adverse events, and safety. Thus, all patients, regardless
of treatment assignment, meet with a study psychiatrist
at all ratings visits throughout the study. Ratings visits
are scheduled to coincide with a treatment visit (whether
CBT or medication) to minimize patient time demands.
For patients randomized to medication, the study
psychiatrist also assesses medication compliance, re-
sponse to treatment, and need for dose adjustment at
each of the ratings visits. For all patients, the psychiatrist
limits the visit to a maximum of 20 min, unless an ur-
gent clinical situation requires greater intervention. The
total time the psychiatrist spends with the patient at
each visit is recorded, and psychiatrists are instructed to
adhere to the Clinical Management Manual developed
by Fawcett et al. [75].
Patients who do not remit (that is, those with an HDRS-
17 total score of ≥8 at either week 10 or week 12) following
12 weeks of monotherapy are offered the option to enter
an additional 12-week course of combination treatment.
Patients who initially received a medication as monother-
apy continue on that medication in a double-blind manner,
and begin the 16-session course of CBT. Patients who ini-
tially received CBT will have open-label escitalopram
added to their treatment, following the same dosing
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chose to use open-label medication in this phase due to in-
adequate power to identify differences between rando-
mized treatments. These patients also meet with their CBT
therapist once per month for a total of three monthly
booster sessions over this 12-week period. The visit struc-
ture for this combination phase treatment replicates that of
the monotherapy phase: weekly ratings visits for 6 weeks,
followed by bi-weekly ratings visits for the next 6 weeks.
At the end of this 12-week combination treatment period
(that is, week 24 from baseline), patients are assessed for
response to the combination treatment (see below). Those
who remit or respond (defined below) can continue into
the long-term follow-up phase (described below) for an
additional 18 months, following the same visit schedule as
the monotherapy phase remitters.Long-term follow-up visits
Patients who are remitters at the end of the acute phase,
or who are remitters or responders at the end of combin-
ation treatment are eligible to enter into long-term follow-
up. These patients return for an assessment at the end of
each 3-month period following the end of their acute
treatment (that is, week 12 for monotherapy remitters,
week 24 for remitters/responders to combination treat-
ment). The assessments at these follow-up visits consist of
a Longitudinal Interval Follow-up Evaluation (LIFE) inter-
view [76], a clinical interview by a psychiatrist, clinical rat-
ings on the HDRS, MADRS, and HARS by a trained
blinded rater, and self-report measures. Patients continue
in the follow-up phase until: (1) 2 years from study base-
line; or (2) depressive recurrence (defined below). If, be-
tween scheduled follow-up phase visits, the patient
reports clinically important return of symptoms and func-
tional impairment such that they desire additional or al-
ternative antidepressant treatment, they are considered to
be at risk for recurrence, and a LIFE will be conducted as
soon as possible.Major endpoints
Remission Remission, the study’s primary outcome
measure, is defined as a HDRS-17 item total score <8 at
both the week 10 and week 12 ratings visits for patients
in the acute monotherapy phase. For patients who enter
the combination treatment phase, remission is defined
as a HDRS-17 item total score <8 at both the week 22
and week 24 ratings visits. Remitters from either the
monotherapy or combination treatment phases are eli-
gible to enter the long-term follow-up phase (21 months
for monotherapy remitters; 18 months for combination
remitters), returning every 3 months for assessments or
until depression recurrence.Response Response is defined as ≥50% reduction from the
baseline HDRS-17 item total score, and response will be
used as a secondary outcome measure. Response is deter-
mined based on the HDRS-17 item rating at the week 12
and week 24 visits. For the non-remitters at week 12, the
week 24 response/non-response status is used to determine
further study participation. Responders at week 24 (that is,
those patients who did not remit during the initial 12-week
monotherapy phase, but who meet criteria for response at
the end of the combination treatment phase) are offered
the option to enter into the long-term follow-up phase.
These patients return every 3 months for assessments for
18 months, or until depression recurrence, following the
same follow-up schedule as the remitting patients. Recur-
rence is defined as the occurrence of any one of the follow-
ing four criteria during the long-term follow-up phase: (1)
Meeting full criteria for a major depressive episode: deter-
mined through a LIFE score of 3 for major depression,
administered by a blind rater; (2) A 17-item HDRS ≥14
score in 2 consecutive weeks: blinded raters will administer
the HDRS at the scheduled follow-up visits. A patient scor-
ing ≥14 at a follow-up visit will be asked to return the sub-
sequent week for a repeat rating. If that rating is also ≥14,
the patient is considered to have had a recurrence; (3) A
17-item HDRS score ≥14 at any follow-up visit, and at
which the patient requests an immediate change in treat-
ment for their depressive symptoms; and (4) High current
risk for suicidality (as assessed by the study psychiatrist)
that warrants urgent intervention.
Predictors
Functional magnetic resonance imaging Recent devel-
opments in image acquisition and data analysis now sug-
gest that resting state studies can be reliably acquired using
blood oxygen level-dependent (BOLD) fMRI [77-79].
Temporally correlated fluctuations in regional activity can
be defined using both model-driven (correlations with spe-
cific seed regions) and data-driven approaches (that is, in-
dependent components analysis or self-organizing maps).
These fluctuations agree with the concept of functional
connectivity, a descriptive measure of spatio-temporal cor-
relations between spatially distinct regions. Using such
methods, decreased low-frequency correlations have been
reported in depression [80-82]. These first results suggest
fMRI can identify network abnormalities comparable to
those previously identified using PET [36,83]. Critical to
the goal of personalized treatment, resting BOLD fMRI
methods can be implemented in scans of individual
patients. Resting-state BOLD fMRI scans are acquired
prior to initiating treatment and at a fixed, early time-point
specific for each treatment. A third fMRI is performed at
the completion of the 12 weeks of acute phase treatment,
to serve as a predictor of recurrence during maintenance
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multivariate analyses and associated with the treatment
outcomes will be used to determine whether pretreatment
brain patterns can distinguish among outcome groups
[82,84]. A second fMRI scan, acquired early in the treat-
ment course, will be used to assess the likelihood of re-
sponse to the specific treatment assigned. These analyses
will serve as a first step towards defining brain-based sub-
types predictive of differential treatment outcome in major
depression. The data from these studies will also be
entered into more complex algorithms integrating imaging
findings with behavioral, environmental, biochemical, and
genetic information for individual patients.
Neuroimaging methods
Imaging acquisition All images are acquired using a 3-
Tesla whole-body MR system (Siemens MAGNETOM
TIM Trio, Siemens Medical Solutions, Erlangen, Germany).
The MR imaging protocol includes: (1) a 3-D anatomic vol-
ume (8 min); (2) resting-state functional connectivity
(7.5 min); and (3) diffusion tensor imaging (DTI) (30 min);
acquisition for a total of under 60 min of scanning. The
anatomic imaging will be conducted for anatomic reference
in fMRI data analysis and volumetric analysis [85]. The DTI
images will be used to refine selection of regions-of-interest
(ROI) for model-based analyses [82,86,87]. The baseline/
resting fMRI acquisition will be used to measure region
connectivity. The Positive and Negative Affective Scale will
be administered before and after the scanning session to as-
sess emotional states at the time of the fMRI [88].
Molecular genetic predictors We collect whole blood
for DNA extraction, and for DNA and lymphoblast bank-
ing at the Rutgers Cell & DNA Repository (http://www.
rucdr.org/) from every consenting patient at the screening
visit. DNA will be used for genotyping genetic polymorph-
isms, mostly single nucleotide polymorphisms (SNPs), in a
series of candidate genes that have emerged from previous
human or animal studies or the ongoing genome-wide as-
sociation studies thought to be relevant for antidepressant
treatment response, including genes from the HPA-axis,
monoaminergic systems, or neurotrophic systems [89].
The study was not powered to test for genome-wide asso-
ciation; however, data from it might be useful in meta-
analyses across studies. The main intent of the DNA ana-
lyses is to examine hypothesized molecular genetic predic-
tors in conjunction with other clinical and biological
predictors to identify subtypes of patients more likely to
respond to or remit with one of the three study treat-
ments. DNA is also collected for future investigation of
epigenetic modifications, including DNA methylation [90].
We extract RNA from whole blood collected in Tempus
blood RNA tubes (Applied Biosystems) at the baselinevisit after randomization and after 2 and 12 weeks of treat-
ment. Analyses measure the expression of specific candi-
date transcripts encoding chaperone and co-chaperone
proteins of the glucocorticoid receptor, using real-time
PCR as well as gene-expression microarrays for a more
comprehensive characterization of blood gene expression
profiles [91]. We also assess the correlation of these gene-
expression patterns with other putative biomarkers (for
example, the Dex/CRH test and inflammatory markers)
and test whether they can be used to predict or monitor
treatment response [92].Neuroendocrine function The Dex/CRH test has been
used to assess HPA axis function in depressed patients
[93]. This test involves oral administration of dexametha-
sone at 2300 h the night prior to the assessment, followed
by intravenous CRH administration at 1500 h the following
afternoon. The CRH can be administered as a fixed dose of
100 mg of human CRH or 1 mg/kg of ovine CRH. At
1500 h, prior to the CRH infusion, and at set intervals for
the following 2 h, plasma samples are collected for cortisol
and adrenocorticotropic hormone (ACTH). In healthy sub-
jects, there is little increase in concentrations of cortisol or
ACTH after administration of CRH because the CRH can
only minimally override the HPA-suppressing effects of
dexamethasone. In many patients with MDD, however, this
test induces substantial increases in plasma ACTH and
cortisol concentrations [94]. The mechanism behind this
effect is presumed to be impaired signaling of the gluco-
corticoid receptor (GR) [95]. Reduced GR sensitivity
diminishes the ability of dexamethasone to suppress the
HPA axis at the level of the pituitary, and it also reduces
the inhibition of CRH and arginine vasopressin release
from the paraventricular nuclei of the hypothalamus, con-
sequently enhancing the stimulatory effects of the exogen-
ously administered CRH [96].
Use of the Dex/CRH test in several studies has demon-
strated HPA axis dysregulation during a major depressive
episode, and normalization of the axis after recovery
[95,97,98]. Sustained non-suppression of the HPA axis in
MDD patients undergoing the Dex/CRH test predicts a
worse prognosis for treatment response [94,99]. Some data
also suggest that this test may predict the risk of depres-
sive relapse [100]. The Dex/CRH test is well tolerated in
medically healthy subjects [101].
For the PReDICT protocol, we conduct the Dex/CRH
test immediately prior to randomization and at the end
of the 12-week acute phase treatment period, using the
protocol described by Heim et al. [102]. We used human
CRH for study participants during the first 2 years of the
study. However, the manufacturer subsequently experi-
enced production difficulties, causing us to switch to
ovine CRH for the remainder of the study.
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firmed that medically healthy subjects with major depres-
sion demonstrate increased circulating concentrations of
the proinflammatory cytokines tumor necrosis factor
(TNF)-alpha, interleukin (IL)-1-beta, and IL-6 as well as
acute phase reactants, especially C-reactive protein (CRP)
[103-105]. Associations between depression and increased
proinflammatory cytokines or CRP have been apparent
across the adult life span, whether comparisons are made
between clinically depressed patients and matched controls
[106] or whether they arise from large population-based
studies [107,108]. Recent investigations have reported posi-
tive correlations between levels of various inflammatory
mediators and depressive symptom severity; furthermore,
the association between immune activation and depression
appears to be robust enough to be detectable in the con-
text of mild depressive symptoms that do not meet criteria
for major depression [109]. Supportive of the idea that in-
flammation is involved in the broader pathophysiology of
MDD, therapeutic administration of cytokines promotes
the development of frank depressive symptoms and syn-
dromes. For example, 40% to 50% of patients receiving
chronic treatment with interferon-alpha (which induces
the production/release of IL-6, IL-1b, and TNF-alpha) de-
velop clinically important depressive symptoms or meet
criteria for major depression within 3 to 6 months of treat-
ment initiation [110]. Relevant to the pathophysiology of
major depression, proinflammatory cytokines are potent
activators of corticotropin-releasing hormone (CRH) path-
ways (that is, the HPA axis and sympathetic nervous
system) [111]. Cytokines appear capable of inhibiting gluco-
corticoid receptor functioning [112] and of diminishing
CNS serotonin signaling capacity by reducing tryptophan
bioavailability and by increasing presynaptic serotonin re-
uptake activity [113,114].
IL-6 and CRP assessment: To further clarify whether IL-
6 and CRP are predictors of treatment response (early or
final), plasma collected at baseline, at a point early in treat-
ment, and at week 12 will be analyzed for concentrations
of IL-6 and CRP. Plasma concentrations of IL-6 will be
determined in duplicate using sandwich ELISA according
to manufacturer‘s protocol (R & D Systems, Minneapolis,
MN, USA) [115]. The mean inter- and intra-assay coeffi-
cients of variation for control samples in this assay are re-
liably 10% or less [116].
Plasma CRP will be assessed with a high-sensitivity tur-
bidimetric assay based within the Emory University Hos-
pital Clinical Laboratories. Sensitivity of the assay is rated at
0.18 mg/L, detection limits of the assay are 0.2 to 80 mg/L,
and functional sensitivity (at 20% CV) is 0.2 mg/L.
Personality Prior research suggests that personality vari-
ables, including personality disorders (PDs), predict the
longitudinal course of MDD in treatment-seeking patients[117,118], although data on personality predictors of re-
sponse to specific treatments are sparse [119]. Perhaps the
central question at the heart of current research on the
classification of personality pathology, which bears on pre-
dictors of treatment outcome, is how best to conceptualize
personality: as categorical PDs; as sums of numbers of
PDs or PD criteria met [117]; as dimensional representa-
tions of syndromes (for example, personality prototypes,
for which patients can vary in the degree to which they
match a given diagnosis [120]); or as dimensional traits
(for example, neuroticism, emotional dysregulation, or
emotional avoidance) [121,122].
We addressed these issues in this study by using mea-
sures that cover the landscape of personality and PD diag-
nosis: (1) The Shedler-Westen Assessment Procedure, 2nd
edition (SWAP-II), an instrument developed for use by
clinically expert observers (much like the HRSD for de-
pression), which yields dimensional DSM-IV PD diagnoses,
empirically-derived PD syndromes, empirically-derived
traits, and empirically-derived scales that describe patients
whose MDD did and did not respond to various forms of
treatment in naturalistic settings [123]; and (2) the Inter-
national Personality Disorders Examination (IPDE) [124], a
semi-structured interview that can yield categorical and di-
mensional data on both the DSM-IV and ICD-10 PDs.
Clinical and demographic variables Clinical and demo-
graphic variables are collected by self-report measures
and structured interviews. Demographic data on gender,
age, race, ethnicity, education level, marital status, em-
ployment status, and living situation are collected from
an intake form completed at the screening visit. Family
psychiatric history is collected using a self-report form
listing major Axis I diagnoses and suicide, and inquiring
which, if any, family members were affected.
Among the data for clinical variables collected are the
self-reported history of childhood trauma using the CTQ
and EHEI, and recent important life events from the Life
Experiences Survey [76]. The self-report Goals scale [125]
and Combined Hassles and Uplifts scale [126] assess
current levels of hopelessness and frustration and are col-
lected at baseline and at intervals throughout the acute
and follow-up phases. Depression and anxiety severity are
assessed by both clinician interview (HDRS, MADRS,
HARS) and self-report forms (QIDS, BDI). History of sub-
stance abuse and dependence and presence of co-morbid
psychiatric conditions are obtained from the SCID
interview.
Data management
A local area network resident relational database (Micro-
soft Office Access 2010, Microsoft, Redmond, WA, USA)
serves as the secure repository for study data. The rela-
tional structure of the database has been optimized via
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[127]. All tables in the relational database fulfill criteria for
third normal form at a minimum, thereby ensuring struc-
tural optimization of the database [127].
The central tables in the relational database include:
(1) [Subject] table with one row per participant and each
row uniquely identified by a HIPAA-compliant subject
number [128]; and (2) [Subject Contact] table with one
row per participant visit and each row uniquely identi-
fied by the combination of the subject number and con-
tact date. Other dependent tables store data regarding
phase of study participation and collection and tracking
of biological samples including aliquot management and
recording of results. Database security is ensured by
hierarchical password-secured access beginning with
password-restricted access to the network followed by
password-restricted access to the database itself. The
database security helps to maintain in the masking of re-
search staff to randomized treatment by restricting ac-
cess to certain segments of the data.
The relational database also aids in assuring data integ-
rity. Real-time (point-of-entry) data validation is implemen-
ted by utilizing: (1) data rules imposed by the table-to-table
relationships of the normalized data (for example, it is im-
possible to enter rating scale data on an erroneous visit
date); (2) item-level range checks and compatibility checks;
(3) double entry of all scales with automated checking for
discrepancies; and (4) summary checks of psychometric
scales utilizing mirrored (redundant) data entry. Other data
validation measures include automated import of labora-
tory results (eliminating transcription errors) and regular
review of automatically-generated data compatibility
reports (for example, report flags as a possible error when
CGI and HDRS values for a patient visit appear to be in-
compatible, triggering review of previously entered data).
Finally, the optimized structure of the relational
database has enabled the a priori development and
implementation of queries and reports that service
routine outside reporting needs (for example, report-
ing to study sponsor, data safety monitoring board,
institutional review board), internal tracking of pro-
gress toward completing study objectives, and export
of HIPAA-compliant study data for import into exter-
nal statistical software packages for data analysis. In
addition, the normalized structure of the database
simplifies fulfillment of ad hoc data requests for add-
itional novel purposes including preliminary data for
other applications, abstract submission, and data
sharing.
Data analyses
The primary data analyses consist of two phases: (1) iden-
tification of significant predictors of treatment response,
both overall and treatment-specific; and (2) building of acomprehensive model of treatment response similar to
those which predict remission and response to treatment
as well as those who suffer a recurrence [129]. The first
phase will use various variable selection methods (for ex-
ample, recursive partitioning [130,131]), as well as differ-
ent measures of discriminating ability (for example,
C statistic or ROC [132], net reclassification improvement
[133]), to determine the best set of predictors that are
both statistically significant and clinically important using
predefined importance criteria. The building of the prog-
nostic model will use established techniques [134] to cre-
ate a model of treatment response that can then be tested
in future research, including quantifying predictors, cali-
brating the model, and possibly adapting it to the clinic
using a points method. All analyses will be performed in
Stata 12.Statistical power/sample size
There are no established ways to determine sample size
for the identification of possible predictors of an out-
come, as it is a fact-finding endeavor and does not test
specific a priori hypotheses. However, the issue of clin-
ical importance is much more paramount in a study of
this nature (that is, while statistically significant predic-
tors are of interest, it is also necessary to determine if
the predictors of interest result in a large enough abso-
lute or relative difference in response between those
with and without the predictor to be clinically meaning-
ful) [135]. In addition, it is clear that smaller but statisti-
cally significant effects will likely be difficult to replicate
and thus reduce the validity of the model for future use.
Given the sample size we intend to recruit over the time
period specified, we will illustrate the effect sizes for
treatment remission versus non-remission, as very few
data on differential treatment response are available. For
these calculations, we assume a 40% remission rate. The
detectable difference is defined as the difference (either
mean or proportion) between the population and the
treatment remitters detectable with the given sample
size, a Type I error rate (α) = 0.01, and a statistical power
of 0.80. We chose an α= 0.01 because the nature of the
model building will require the testing of multiple pre-
dictors. Population values are determined from various
published and unpublished data (Table 1).
Thus a sample size of 400 will be adequate to detect
moderate to large effect sizes in treatment remission
predictors [136]. Although the sample sizes for differen-
tial remission by treatments will be less, with a projected
overall remission rate of 30% in any group, there will be
approximately 40 remitters in each group to detect the
statistically significant interactions. These are reasonable
numbers for the detection of large interaction effect
sizes [136].
















Endpoint HDRS score 16.0 (4.9) −1.9 0.39 −2.5 0.51
Serotonin transporter gene carriers
(minor allele carriers/Caucasian)
59.9% 17% 0.31 22% 0.40
Elevated C-reactive protein
(>0.22 mg/dl)
21% 13% 0.36 16% 0.48
fMRI brain score 44.1 (4.3) 1.7 0.40 2.2 0.51
Baseline Dex/CRH response
(cortisol AUC, (ng*min)/mL)
2730.6 (266) 104.6 0.39 136.1 0.51
Interleukin-6 (pg/mL) 6.3 (1.4) 0.6 0.43 0.7 0.50
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Given that all treatments provided in the study are stand-
ard first-line treatments for MDD with well-established
safety and tolerability profiles, the DSMB (a four-member
panel of experienced psychiatry researchers) conducts
reviews at yearly intervals during the study. Reports to the
DSMB include all adverse events and any potential confi-
dentiality breaches occurring during the study. Addition-
ally, all serious adverse events that occur in the study are
reported to the DSMB within 1 week of their occurrence.
Because this is not a comparative efficacy trial, but rather
a study of the moderators and mediators of standard first-
line treatments at the level of the individual, the DSMB
does not routinely receive efficacy outcome data, though
such data are provided if requested.
Discussion
Previous treatment with psychotherapy or medication may
impact subsequent response to treatment and may produce
persisting biological, behavioral, cognitive, and emotional
changes [137]. Thus, we chose to examine predictors of
treatment outcomes in patients never previously treated for
depression. To make the trial reflect real-world decisions,
we examined not only medication versus psychotherapy,
but two different medications; all three treatments are cur-
rently considered potential first-line interventions. The de-
sign considered the primary treatment decisions to be
made from the start of care including: (1) whether to initi-
ate treatment with medication or psychotherapy; and (2) if
a medication option is selected, which is the most appropri-
ate specific class of medication. Thus, we designed a three-
armed trial to evaluate clinical, biological, genetic, and per-
sonality factors that may predict outcomes to common
first-line treatment options for MDD. The study was fur-
ther designed to expect that while individual measures
might prove predictive, the more likely outcome would be
that a combination of clinical, imaging, and genetic markers
would predict outcomes to individual treatments. Thestudy design and unique patient population we have chosen
has limitations, and alternative designs were carefully con-
sidered. We did not include a placebo control group or
extended placebo lead-in because it would undoubtedly re-
sult in a marked reduction in the number patients willing
to enter the study. To maximize generalizability and feasi-
bility, we chose our medication treatments from the classes
of antidepressants most commonly used to treat depres-
sion; those classes are SSRIs, SNRIs, and bupropion. Be-
cause anxiety disorders are highly co-morbid with major
depression, and because the presence of a co-morbid anx-
iety disorder (other than OCD) was not an exclusion criter-
ion for entry into the study, bupropion was not selected.
Unlike SSRIs and SNRIs, bupropion does not have an
FDA-indication for the treatment of anxiety disorders, and
is associated with poorer response than SSRIs in treating
depressed patients with high levels of anxiety [138].
Among the SSRIs, we opted for escitalopram because it is
the most selective SSRI, having no or very little effects on
norepinephrine or dopamine reuptake. In contrast, paroxe-
tine is an antagonist of both the serotonin transporter
(SERT) and norepinephrine transporter (NET) [139]. Esci-
talopram has the lowest likelihood of drug-drug interac-
tions of any of the SSRIs [140]. Adverse effect rates with
escitalopram are lower than with citalopram, which we
expected to benefit patient retention in the study. Although
one of the antidepressants clearly needed to be an SSRI,
arguments could be made to replace duloxetine with any of
the following: venlafaxine, mirtazapine, bupropion, nefaza-
done, a tricyclic antidepressant (TCA), or a monoamine
oxidase inhibitor (MAOI). We opted against mirtazapine,
nefazadone, TCAs, and MAOIs due to issues of lower toler-
ability and frequency of clinical use. Duloxetine was
selected over venlafaxine as the SNRI for several reasons.
First, the FDA-approved dose range of venlafaxine is much
broader, and therefore less comparable to escitalopram.
Second, venlafaxine has a more adverse cardiovascular tox-
icity profile, and it may have a greater overdose liability
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primarily through SERT inhibition, with higher doses
required to achieve NET inhibition [142,143].
Interpersonal psychotherapy is another form of psycho-
therapy we could have included, but we did not possess
the statistical power to add another treatment arm, and
the supporting data for the efficacy of CBT are more ex-
tensive. Other limitations include the omission of geriatric
depression - necessary because of the growing evidence
suggesting that vascular depression, which accounts for a
sizeable percentage of the geriatric depressed population,
is truly a distinct neurobiological entity [144]. Also
excluded are patients with clinically important co-morbid
medical disorders or substance abuse, children and adoles-
cents, and those with psychotic depression. Although
these patients are of interest, we believe that the benefits
of keeping our patient characteristics as free of potential
confounding variables as possible will maximize our ability
to examine our primary objectives.
We believe this study design best allows for assess-
ment of the effects of several potentially important mod-
erators and mediators of treatment outcomes, as well as
the interactions between moderators, in a sample
unconfounded by previous treatment effects. The results
of this study should inform clinical treatment decisions
and identify future research approaches to further im-
prove the care of depressed patients.
Trial status
Recruitment for this trial was ongoing at the time this
manuscript was submitted and is expected to continue
through March 2013.
Endnotes
aWe originally intended to recruit 600 patients for PRe-
DICT, but subject recruitment efforts with the current
inclusion/exclusion criteria resulted in the reduction to
400 as the expected total number of subjects that will be
successfully recruited and randomized to participation in
this project.
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